Management of Chronic Seronegative Inflammatory Arthritis with Comorbidities

Disease Assessment and Current Status

A patient with chronic seronegative inflammatory arthritis has erosive, deforming polyarthritis affecting multiple joints, with current therapy providing only moderate symptomatic control and persistent inflammation, according to the Annals of the Rheumatic Diseases 1
The patient has previously been treated with methotrexate, hydroxychloroquine, and intra-articular steroids, but with inadequate long-term efficacy, as reported in the Annals of the Rheumatic Diseases 1
No biologic or JAK inhibitor therapy has been initiated yet, as stated in the Annals of the Rheumatic Diseases 1

The European League Against Rheumatism (EULAR) recommends adding a biologic DMARD or targeted synthetic DMARD when the treatment target is not achieved with the first csDMARD strategy and poor prognostic factors are present, as reported in the Annals of the Rheumatic Diseases 1
TNF inhibitors are recommended as first-line biologic therapy for patients with inadequate response to csDMARDs, according to the Mayo Clinic Proceedings 2
For patients with multiple cardiovascular risk factors, TNF inhibitors have a more favorable safety profile compared to JAK inhibitors, as stated in the Annals of the Rheumatic Diseases 1, 3

The patient's treatment response should be assessed at 3 months, and if no improvement is seen, alternative biologic therapy should be considered, as recommended in the Annals of the Rheumatic Diseases 1
Complete blood count, liver function tests, and inflammatory markers should be monitored every 2-3 months, as stated in the Annals of the Rheumatic Diseases 1
Screening for tuberculosis and hepatitis is necessary prior to initiating therapy, as reported in the Annals of the Rheumatic Diseases 1

If TNF inhibitor therapy fails, consideration should be given to switching to a different mechanism of action, such as IL-6 inhibitors or T-cell co-stimulation modulators, according to the Mayo Clinic Proceedings 2